The vaccinia virus is the "live virus" used in the smallpox vaccine. It is a "pox"-type virus related to smallpox. When given to humans as a vaccine, it helps the body to develop immunity to smallpox. The smallpox vaccine does not contain the smallpox virus and it cannot cause smallpox.
In a new study, researchers explored the crystalline structure of the monkeypox (MPX) virus (MPXV) and the complex of VP39, a 2′-O-RNA methyltransferase (MTase) and sinefungin, a pan-MTase inhibitor.
Researchers opined on the use of live-attenuated whole virus vaccines as COVID-19 vaccines.
A recent study provides an overview of existing literature on the complications of infection with both smallpox and monkeypox virus.
A new review to be posted in the Virus Research journal aims to provide an overview of the recent advances reported concerning hMPXV virology.
A new review published in The Lancet Infectious Diseases aimed to describe the efficacy of vaccinia virus-based smallpox vaccines against the current monkeypox outbreak.
In a new study, researchers assessed the immunogenicity, safety, and booster-efficacy of the Modified Vaccinia virus Ankara-Bavarian Nordic (MVA-BN) vaccine currently being used for immunization against monkeypox.
A new study describes the changes in immune T cell profile over time following monkeypox infection.
esearchers measured the monkeypox virus-neutralizing antibodies produced by the vaccinia virus vaccine, modified vaccinia virus Ankara vaccine, and monkeypox virus to understand the efficacy of the MVA-Bavarian Nordic vaccine currently being used against monkeypox.
In a new study, a team of researchers studied different antigens targeted by vaccinia virus (VACV)- and monkeypox virus (MPXV)-specific T cells.
New research has suggested that recommended vaccinia virus (VACV)-based vaccines will mount a robust immune response against the monkeypox virus observed in the current outbreak (MPXV-2022).
In a recent study published in the journal Vaccines, scientists reviewed all relevant literature to find the available vaccines and therapeutics to prevent MPV.
Researchers reviewed the epidemiology, clinical character, treatment, and prevention of human monkeypox.
Researchers performed an analysis of molecular variance in 59 haplotypes of the IFNAR gene, departing from monkeypox virus, camelpox virus, buffalopox virus, ectromelia virus, cowpox virus, rabbitpox virus, variola virus, and vaccinia virus.
A new study published in the Viruses journal aimed to investigate the cross-reactivity of VACV-based vaccines against the MPXV viruses responsible for the 2022 outbreak.
A recent review by Barbara S. Schnierle of the Paul-Ehrlich-Institut, Germany, and published in the journal Viruses summarized the existing knowledge about MPXV, the disease it causes, and the strategies to curb its spread.
A new review sheds light on the origins of this virus and recently acquired knowledge about its disease mechanism and the preventive and therapeutic measures appropriate in this situation.
In a new study, researchers pursued two monkeypox virus (MPXV) immune targets, A35R and H3L, that could be deployed in a serological assay to identify recent MPXV cases.
A recent study investigated ‘targets’ in the poxvirus and identified the protein residues active in MPV, following which eight potential anti-viral drugs were proposed.
In a new study, researchers explored the driving factors of the vaccinia virus assembly across infected cells.
In newly released research, investigators determined the inactivation of monkeypox virus (MPXV) by heat treatment.